Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 175

1.

Increased chromogranin a cell density in the large intestine of patients with irritable bowel syndrome after receiving dietary guidance.

Mazzawi T, Gundersen D, Hausken T, El-Salhy M.

Gastroenterol Res Pract. 2015;2015:823897. doi: 10.1155/2015/823897. Epub 2015 Mar 30.

2.

Ultrasonography in gastroenterology.

Ødegaard S, Nesje LB, Hausken T, Gilja OH.

Scand J Gastroenterol. 2015 Jun;50(6):698-707. doi: 10.3109/00365521.2015.1028436. Epub 2015 Mar 26.

PMID:
25812623
3.

Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome.

El-Salhy M, Hatlebakk JG, Gilja OH, Hausken T.

Peptides. 2015 May;67:12-9. doi: 10.1016/j.peptides.2015.02.008. Epub 2015 Mar 9.

4.

The effect of body position on postprandial perceptions, gastric emptying, and intragastric meal distribution: an ultrasonographic study in reclining healthy subjects.

Valeur J, Berstad A, Hausken T.

Scand J Gastroenterol. 2015 Feb;50(2):170-3. doi: 10.3109/00365521.2014.990506. Epub 2014 Dec 17.

PMID:
25515140
5.

Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, mesenteric blood flow, and glycemic responses to intraduodenal glucose in healthy older subjects.

Trahair LG, Horowitz M, Hausken T, Feinle-Bisset C, Rayner CK, Jones KL.

J Clin Endocrinol Metab. 2014 Dec;99(12):E2628-34. doi: 10.1210/jc.2014-2475.

PMID:
25210879
6.

High consumption of farmed salmon does not disrupt the steady state of persistent organic pollutants (POP) in human plasma and adipose tissue.

Hausken T, Skaare JU, Polder A, Haugen M, Meltzer HM, Lundebye AK, Julshamn K, Nygård O, Berge RK, Skorve J.

J Toxicol Environ Health A. 2014;77(20):1229-50. doi: 10.1080/15287394.2014.926262.

PMID:
25208663
7.

Bowel perfusion measured with dynamic contrast-enhanced ultrasound predicts treatment outcome in patients with Crohn's disease.

Saevik F, Nylund K, Hausken T, Ødegaard S, Gilja OH.

Inflamm Bowel Dis. 2014 Nov;20(11):2029-37. doi: 10.1097/MIB.0000000000000159.

8.

Increased gastric chromogranin A cell density following changes to diets of patients with irritable bowel syndrome.

Mazzawi T, Gundersen D, Hausken T, El-Salhy M.

Mol Med Rep. 2014 Nov;10(5):2322-6. doi: 10.3892/mmr.2014.2498. Epub 2014 Aug 18.

9.

Stomach antral endocrine cells in patients with irritable bowel syndrome.

El-Salhy M, Gilja OH, Hatlebakk JG, Hausken T.

Int J Mol Med. 2014 Oct;34(4):967-74. doi: 10.3892/ijmm.2014.1887. Epub 2014 Aug 8.

10.

Chromogranin A cells in the stomachs of patients with sporadic irritable bowel syndrome.

El-Salhy M, Gilja OH, Hausken T.

Mol Med Rep. 2014 Oct;10(4):1753-7. doi: 10.3892/mmr.2014.2472. Epub 2014 Aug 8.

11.

Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome.

Mazzawi T, Hausken T, Gundersen D, El-Salhy M.

Eur J Clin Nutr. 2015 Apr;69(4):519-24. doi: 10.1038/ejcn.2014.151. Epub 2014 Aug 6.

12.

Duodenal chromogranin a cell density as a biomarker for the diagnosis of irritable bowel syndrome.

El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T.

Gastroenterol Res Pract. 2014;2014:462856. doi: 10.1155/2014/462856. Epub 2014 Jun 16.

13.

Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (review).

El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T.

Int J Mol Med. 2014 Aug;34(2):363-71. doi: 10.3892/ijmm.2014.1811. Epub 2014 Jun 17. Review.

14.

Endocrine cells in the oxyntic mucosa of the stomach in patients with irritable bowel syndrome.

El-Salhy M, Gilja OH, Gundersen D, Hausken T.

World J Gastrointest Endosc. 2014 May 16;6(5):176-85. doi: 10.4253/wjge.v6.i5.176.

15.

Amelioration of severe TNBS induced colitis by novel AP-1 and NF- κ B inhibitors in rats.

El-Salhy M, Umezawa K, Gilja OH, Hatlebakk JG, Gundersen D, Hausken T.

ScientificWorldJournal. 2014 Jan 30;2014:813804. doi: 10.1155/2014/813804. eCollection 2014.

16.

Endocrine cells in the ileum of patients with irritable bowel syndrome.

El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T.

World J Gastroenterol. 2014 Mar 7;20(9):2383-91. doi: 10.3748/wjg.v20.i9.2383.

17.

Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment.

El-Salhy M, Hatlebakk JG, Gilja OH, Hausken T.

Expert Rev Gastroenterol Hepatol. 2014 May;8(4):435-43. doi: 10.1586/17474124.2014.888952. Epub 2014 Mar 3. Review.

PMID:
24580043
18.

Is irritable bowel syndrome an organic disorder?

El-Salhy M, Gundersen D, Gilja OH, Hatlebakk JG, Hausken T.

World J Gastroenterol. 2014 Jan 14;20(2):384-400. doi: 10.3748/wjg.v20.i2.384. Review.

19.

[Does silibinin have a place in the treatment of liver diseases?].

Lied GA, Gilja OH, Hausken T.

Tidsskr Nor Laegeforen. 2014 Feb 25;134(4):392. doi: 10.4045/tidsskr.13.1531. Norwegian. No abstract available.

20.

Abnormal rectal endocrine cells in patients with irritable bowel syndrome.

El-Salhy M, Gundersen D, Hatlebakk JG, Gilja OH, Hausken T.

Regul Pept. 2014 Jan 10;188:60-5. doi: 10.1016/j.regpep.2013.11.005. Epub 2013 Dec 6.

PMID:
24316398
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk